Transparency 2012 Comment Letter

The CPC’s comment letter to FDA requesting greater openness and transparency by the Agency in utilizing and incorporating public input in the following areas of concern:
• The production of guidance documents to address combination product questions.
• The release of information about combination products.
• FDA’s response to industry comments and other input related to draft guidance documents published by the Agency.